Monoclonal Antibodies in Lymphoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: 30 September 2025 | Viewed by 1909
Special Issue Editor
Special Issue Information
Dear Colleagues,
The introduction of monoclonal antibodies (MoAbs) into clinical practice has significantly improved the prognosis of many hematological malignancies, representing a milestone in the field of precision medicine.
Used in monotherapy or, more often, in combination with chemotherapy, MoAbs are currently essential in the treatment of lymphoid neoplasms.
MoAbs are able to target specific cancer antigens, using direct or indirect immunological killing to address cytotoxic agents to neoplastic cells, to recruit and activate immune effector cells, and to antagonize cell exhaustion.
In this Special Issue, we would like to provide an overview of the biological basis and the current clinical use of MoAbs and of the optimal combination regimens and sequential schemes, with a look towards future therapeutic perspectives.
Dr. Donato Mannina
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- monoclonal antibodies
- immunotherapy
- drug immunoconiugates
- bispecific antibodies
- checkpoints inhibitors
- NHL
- HL
- CLL
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
